Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 6Phase 1/2 3Phase NA 2Phase 2/3 2Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 18Rectal Neoplasms 7Colorectal Neoplasms 5Carcinoma, Intraductal, Noninfiltrating 4Neoplasms 3Breast Carcinoma In Situ 3Urinary Bladder Neoplasms 2Sarcoma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Colonic Neoplasms 2Bites and Stings 2Uterine Cervical Neoplasms 1Testicular Neoplasms 1Stress, Psychological 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Seminoma 1Rhabdoid Tumor 1Retinoblastoma 1Prostatic Neoplasms 1Peritoneal Metastases From Gastric Cancer 1Peritoneal Metastases From Colorectal Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm, Residual 1Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer 1Muscle Invasive Bladder Cancer 1Motor Activity 1

Interventions

Radiotherapy 8camrelizumab 3Drug Therapy 3Cisplatin 3sintilimab 2Paclitaxel 2Neoadjuvant Therapy 2toripalimab 1tislelizumab 1pembrolizumab 1durvalumab 1anlotinib 1Surgical Procedures, Operative 1Radiofrequency Ablation 1Radiation 1Poly(ADP-ribose) Polymerase Inhibitors 1Observation 1Narrow Band Imaging 1Magnetic Resonance Spectroscopy 1Laparoscopy 1Immune Checkpoint Inhibitors 1Gene Expression Profiling 1Fluorouracil 1Fluorodeoxyglucose F18 1Esophagectomy 1Endoscopy, Digestive System 1Docetaxel 1Consolidation Chemotherapy 1Chemoradiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Esophageal Squamous Cell Carcinoma × Neoadjuvant Therapy × Clear all
NCT07236320 2025-11-19

Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC

Sichuan Cancer Hospital and Research Institute

Phase NA Completed
200 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06762158 2025-01-07

NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC

RenJi Hospital

Phase NA Active not recruiting
50 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡